Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...
Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration ...
Point-of-care testing for common sexually transmitted infections may reduce overuse of antibiotics and improve emergency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback